Figure 2

Nfkb2 suppression in precancerous Myc-transgenic B cells and Myc-driven lymphomas. a) real-time PCR analysis of c-Myc, Nfkb2 and p21 mRNA levels in bone marrow (BM) and splenic (spleen) B220⁺ wild type (wt, grey bars) and precancerous Eμ-Myc (Eμ, black bars) B cells. Levels of mRNA are standardized to the expression of Ubiquitin (Ub), which is not regulated by Myc. * indicates p < 0.05. b) immunoblot analyses of the indicated proteins in control and precancerous Eμ-Myc B220⁺ B cells from bone marrow (BM) and spleen. c) real-time PCR analysis of Nfkb2 expression in ten Eμ-Myc lymphomas or splenic wild type (wt) B220⁺ B cells. d) immunoblot analysis of NF-κB2 p100 and p52 expression in wild type (wt) and Eμ-Myc precancerous B220⁺ B cells and Eμ-Myc lymphomas. Nfkb2 ^-/- and Nfkb1 ^-/- B220⁺ B cells served as controls. e) real-time PCR analysis of NFKB2 expression in seventeen human Burkitt lymphoma samples compared to CD19⁺ control B cells. Levels of mRNAs were normalized to the expression of Ubiquitin (Ub).